文献速递造血干细胞移植与细胞治疗

从干细胞供者或第三方供者转移微操作CMV特异性T细胞治疗allo-HSCT后CMV感染

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
PubMed 文献 · Leukemia · 2017-01-16

这项I/IIa期前瞻性试验评估了干细胞供者或第三方供者来源的CMV特异性T细胞治疗allo-HSCT后持续性CMV感染的安全性和有效性。44例患者接受筛查,8例T细胞去除移植受者接受了干细胞供者来源的T细胞治疗,病毒学完全和部分应答率分别为62.5%和25%。57例CMV血清学阴性供者移植患者中仅8例接受了部分HLA匹配的第三方供者T细胞,除1例外第三方来源T细胞均未检出。

要点

  • T细胞去除移植受者接受干细胞供者CMV特异性T细胞后,病毒学完全应答率62.5%、部分应答率25%。
  • 所有接受治疗的患者中CMV表位特异性T细胞均变得可检测。
  • 第三方供者T细胞因HLA匹配不理想,在8例中7例未能检出扩增。

核心结论

  • 过继转移与T细胞去除移植受者中功能性病毒特异性T细胞重建相关。
  • 次优HLA匹配可能抵消CMV血清学阴性患者中第三方供者来源病毒特异性T细胞的扩增。

研究设计与样本

  • I/IIa期前瞻性试验,评估干细胞供者或第三方供者来源CMV特异性T细胞治疗allo-HSCT后持续性CMV感染的安全性和有效性。
  • 筛查44例接受CMV血清学阳性供者移植的allo-HSCT患者,其中T细胞充足移植28例(D+ repl)、T细胞去除移植16例(D+ depl)。
  • 8例D+ depl受者接受了来自其干细胞供者的过继T细胞治疗。
  • 57例接受CMV血清学阴性供者移植的CMV患者中,仅8例因第三方供者鉴定耗时接受了部分HLA匹配的第三方供者抗原特异性T细胞。

主要发现

  • 8例接受干细胞供者T细胞治疗的D+ depl患者中,CMV表位特异性T细胞均变得可检测。
  • 病毒学完全应答率为62.5%,部分应答率为25%。
  • 8例接受第三方供者T细胞的患者中,除1例外第三方供者来源CMV特异性T细胞均未检出。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytomegalovirus (CMV) infection is a common, potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We assessed prospectively the safety and efficacy of stem cell-donor- or third-party-donor-derived CMV-specific T cells for the treatment of persistent CMV infections after allo-HSCT in a phase I/IIa trial. Allo-HSCT patients with drug-refractory CMV infection and lacking virus-specific T cells were treated with a single dose of ex vivo major histocompatibility complex-Streptamer-isolated CMV epitope-specific donor T cells. Forty-four allo-HSCT patients receiving a T-cell-replete (D+ repl; n=28) or T-cell-depleted (D+ depl; n=16) graft from a CMV-seropositive donor were screened for CMV-specific T-cell immunity. Eight D+ depl recipients received adoptive T-cell therapy from their stem cell donor. CMV epitope-specific T cells were well supported and became detectable in all treated patients. Complete and partial virological response rates were 62.5% and 25%, respectively. Owing to longsome third-party donor (TPD) identification, only 8 of the 57 CMV patients transplanted from CMV-seronegative donors (D-) received antigen-specific T cells from partially human leukocyte antigen (HLA)-matched TPDs. In all but one, TPD-derived CMV-specific T cells remained undetectable. In summary, adoptive transfer correlated with functional virus-specific T-cell reconstitution in D+ depl patients. Suboptimal HLA match may counteract expansion of TPD-derived virus-specific T cells in D- patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Neuenhahn M, Albrecht J, Odendahl M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia. 2017. PMID: 28090089. doi:10.1038/leu.2017.16

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。